<DOC>
	<DOCNO>NCT01747876</DOCNO>
	<brief_summary>LEE011 small molecule inhibitor CDK4/6 . LEE011 demonstrate vitro vivo activity tumor model . The primary purpose study determine maximum tolerate dose ( MTD ) and/or recommend dose expansion ( RDE ) pediatric patient delineate clinical dose use future study . This study also assess safety , tolerability , PK preliminary evidence antitumor activity LEE011 patient MRT neuroblastoma .</brief_summary>
	<brief_title>Study Safety Efficacy Patients With Malignant Rhabdoid Tumors ( MRT ) Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Rhabdoid Tumor</mesh_term>
	<criteria>Confirmed diagnosis MRT , neuroblastoma dose escalation part , tumor document evidence DcyclinCDK4/6INK4aRb pathway abnormality ( dose escalation part ) , Patients CNS disease stable dos steroid least 7 day prior first dose LEE011 plan escalation . In expansion part , patient must least one measurable disease define RECIST v1.1 . Patients must Lansky ( ≤ 16 year ) Karnofsky ( &gt; 16 year ) score least 50 . Prior history QTc prolongation QTcF &gt; 450 m screen ECG . Patients follow laboratory value screen : Serum creatinine &gt; 1.5 x upper limit normal ( ULN ) age Total bilirubin &gt; 1.5 x ULN age Alanine aminotransferase ( ALT ) /serum glutamic pyruvic transaminase ( SGPT ) &gt; 3 x ULN age ; aspartate aminotransferase ( AST ) /serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 3 x ULN age except patient tumor involvement liver must AST/SGOT ALT/SGPT ≤ 5 x ULN age . For purpose study , ULN SGPT/ALT 45 U/L . Patients currently receive treatment agent metabolize predominantly CYP3A4/5 narrow therapeutic window and/or agent know strong inducer inhibitor CYP3A4/5 prohibit . In particular , enzymeinducing antiepileptic drug ( EIAEDs ) . Other severe acute chronic medical psychiatric condition laboratory abnormality may interfere interpretation study result , judgment investigator would make patient inappropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>pediatric</keyword>
	<keyword>CDK4/6 inhibitor</keyword>
	<keyword>dose escalation</keyword>
	<keyword>malignant rhabdoid tumor</keyword>
	<keyword>MRT</keyword>
	<keyword>neuroblastoma</keyword>
</DOC>